Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03631355 · ClinicalTrials.gov registry record · Phase 4
Reducing Hemarthrosis in ACL Reconstruction With BTB Autograft by the Administration of Intravenous TXA
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 110
- Enrollment target
NCT03631355 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 110 participants.
The verdict
NCT03631355, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of the proposed study is to evaluate the effects of administering intravenous tranexamic acid (TXA) to patients undergoing anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone autograft to minimize hemarthrosis within the knee joint and post operative pain.
Interventions
- DRUG Tranexamic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2018-06-06 |
| Est. Completion | 2020-03-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03631355
The ClinicalTrials.gov registry entry for NCT03631355 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tranexamic Acid is the first listed.
NCT03631355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03631355 about?
NCT03631355 is a clinical study titled "Reducing Hemarthrosis in ACL Reconstruction With BTB Autograft by the Administration of Intravenous TXA". The purpose of the proposed study is to evaluate the effects of administering intravenous tranexamic acid (TXA) to patients undergoing anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone autograft to minimize hemarthrosis within the knee joint and post operative pain.
What is the current status of trial NCT03631355?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2018-06-06. Estimated completion is 2020-03-01.
What interventions are being tested in trial NCT03631355?
The interventions under investigation include: Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT03631355?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.